Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis.
Level 4 - case-series / case-control
Case series of four patients with toxic drug exposure
PubMed 6823561 · doi:10.1126/science.6823561
What was done
Clinical evaluation of four individuals who developed marked parkinsonism after intravenous use of an illicit synthetic meperidine analog. Chemical analysis was conducted on the injected substance recovered from two patients, and findings were assessed alongside pathological data from a previously published case.
What was found
Chemical analysis of the substance injected by two patients revealed it to be primarily 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) with trace amounts of 1-methyl-4-phenyl-4-propionoxy-piperidine (MPPP). All four individuals developed marked parkinsonian symptoms following exposure. The abstract reports no numerical clinical scores or quantitative effect sizes.
Why it matters
This study identified MPTP as a potent neurotoxin capable of causing selective substantia nigra damage and severe chronic parkinsonism in humans, laying the groundwork for MPTP models of Parkinson's disease.
Limits
Small sample size (n = 4), uncontrolled case series design, and chemical analysis was available for only two of the four patients. Pathological evidence was inferred from one previously reported case rather than direct post-mortem analysis of this cohort.
Cited by
- supports MPTP is a mitochondrial-targeting contaminant of illicit intravenous drugs from the 1980s that causes Parkinson's disease.